SV

Street Verdict

Analyst Scorecard

A record of what Choice Institutional Equities Analysis said publicly, with the source. Not advice.

“Neutral on Dr. Reddy's Laboratories, with a target price of ₹1,274, indicating no major upside from current levels. The company is in an investment phase, strengthening its product pipeline with key launches like GLP-1 and biosimilars to offset Revlimid losses, but this, along with US generics pricing pressure, has led to higher SG&A expenses.”

Choice Institutional Equities Analysis’s track record (trackable calls only): 77 graded calls · 95% CI 35–57%

Dr. Reddy's LaboratoriesNeutralCalled 24 Jul 2025
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee Choice Institutional Equities Analysis’s full track record